Last reviewed · How we verify
SB204 2%
At a glance
| Generic name | SB204 2% |
|---|---|
| Also known as | NVN1000 |
| Sponsor | Novan, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (PHASE2)
- A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel (PHASE1)
- A Phase 1 Study Assessing Local Cutaneous Effects of SB204 (PHASE1)
- A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB204 2% CI brief — competitive landscape report
- SB204 2% updates RSS · CI watch RSS
- Novan, Inc. portfolio CI